Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.19x

Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) has a Cash Flow Reinvestment Rate of 0.19x as of September 2025, reinvesting CN¥54.40 Million (capex CN¥54.40 Million ) from operating cash flow of CN¥281.88 Million. See free cash flow generation of Shaanxi Meibang Pharmaceutical Group Co to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.19x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥54.40 Million
Capex + Investments

Operating Cash Flow

CN¥281.88 Million
CNY

Capital Expenditures

CN¥54.40 Million
CNY

Shaanxi Meibang Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate (2017–2024)

Historical reinvestment intensity for Shaanxi Meibang Pharmaceutical Group Co Ltd across 7 annual periods. For the full cash flow conversion analysis, see Shaanxi Meibang Pharmaceutical Group Co (605033) cash conversion ratio.

Annual Cash Flow Reinvestment Rate for Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)

Year-by-year capital reinvestment analysis for Shaanxi Meibang Pharmaceutical Group Co Ltd. See Shaanxi Meibang Pharmaceutical Group Co (605033) financial flexibility to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 1.92x CN¥539.05 Million CN¥280.40 Million CN¥158.81 Million ▲ +123.3%
2023 0.86x CN¥288.20 Million CN¥334.79 Million CN¥203.69 Million ▼ -24.3%
2022 1.14x CN¥143.69 Million CN¥126.41 Million CN¥109.29 Million ▼ -19.1%
2020 1.40x CN¥105.20 Million CN¥74.88 Million CN¥61.71 Million ▲ +218.4%
2019 0.44x CN¥56.69 Million CN¥128.45 Million CN¥33.78 Million ▼ -78.5%
2018 2.06x CN¥34.86 Million CN¥16.96 Million CN¥34.86 Million ▲ +244.2%
2017 0.60x CN¥17.56 Million CN¥29.41 Million CN¥17.56 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow